Exenatide elicits sustained glycaemic control and progressive reduction of body weight in patients with type 2 diabetes inadequately controlled by sulphonylureas with or without metformin.

Riddle MC, Henry RR, Poon TH, Zhang B, Mac SM, Holcombe JH, Kim DD, Maggs DG

Diabetes/metabolism research and reviews1 Nov 2006Cited by 70 (Europe PMC)

PMID16634116DOI10.1002/dmrr.646PepBankPUB-16634116

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

01HumanNon-randomized trialEfficacy outcome
In patients with type 2 diabetes, HbA1c reduction with exenatide persisted to week 82 at 1.0% below baseline.
In plain wordsHbA1c remained 1.0% below baseline after 82 weeks of exenatide.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseHbA1c change at week 82
Study
n = 222
Outcome group
Glycemic control · Metabolic and weight
Studied dose
10 microg twice daily · 82 weeksAs given in this study (human).
Measurements
HbA1c change
−1%
week 82
Source sentences
Summary
Reduction in HbA(1c) from baseline to week 30 (-0.8 +/- 0.1% and -1.0 +/- 0.1% for 5 microg b.i.d. and 10 microg b.i.d., respectively [mean +/- SE]) was sustained up to week 82 (-1.0 +/- 0.1%).
2 context sentences(design, population, supporting numbers)
Summary · context
Both 30-week, placebo-controlled trials of 5 microg or 10 microg exenatide b.i.d. were followed by 52-week open-label, uncontrolled extension studies in which all participants received 10 microg exenatide b.i.d. and continued prior oral therapies.
Summary · context
This interim analysis includes data for 222 patients who completed 82 weeks of exenatide treatment (61% M, age 57 +/- 10 y, weight 99 +/- 21 kg, BMI 34 +/- 6 kg/m(2), HbA(1c)8.4 +/- 1.0% [mean +/- SD]).
Report a problemFND-1663411603
02HumanNon-randomized trialEfficacy outcome
In patients with type 2 diabetes, exenatide reduced weight by 4.0 kg from baseline at week 82.
In plain wordsWeight fell 4.0 kg from baseline after 82 weeks of exenatide.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseWeight change at week 82
Study
n = 222
Outcome group
Body weight · Metabolic and weight
Studied dose
10 microg twice daily · 82 weeksAs given in this study (human).
Measurements
Weight change
−4 kg
week 82
Source sentences
Summary
Reduction of body weight from baseline to week 30 (-1.4 +/- 0.3 kg and -2.1 +/- 0.3 kg for 5 microg b.i.d. and 10 microg b.i.d., respectively) was progressive up to week 82 (-4.0 +/- 0.3 kg).
2 context sentences(design, population, supporting numbers)
Summary · context
Both 30-week, placebo-controlled trials of 5 microg or 10 microg exenatide b.i.d. were followed by 52-week open-label, uncontrolled extension studies in which all participants received 10 microg exenatide b.i.d. and continued prior oral therapies.
Summary · context
This interim analysis includes data for 222 patients who completed 82 weeks of exenatide treatment (61% M, age 57 +/- 10 y, weight 99 +/- 21 kg, BMI 34 +/- 6 kg/m(2), HbA(1c)8.4 +/- 1.0% [mean +/- SD]).
Report a problemFND-1663411607
03HumanNon-randomized trialEfficacy outcome
Among patients with baseline HbA1c above 7%, 44% achieved HbA1c at or below 7% after 82 weeks of exenatide.
In plain wordsAfter exenatide, 44% of patients whose starting HbA1c exceeded 7% reached 7% or less at week 82.
Peptide
Exenatide (exendin-4)
Outcome
Not applicableHbA1c target attainment
Study
n = 207
Outcome group
Glycemic control · Metabolic and weight
Studied dose
10 microg twice daily · 82 weeksAs given in this study (human).
Measurements
Patients reaching HbA1c <=7%
44%
week 82, baseline HbA1c >7%
Source sentences
Summary
Of 207 patients with baseline HbA(1c) > 7%, 44% achieved HbA(1c) < or = 7% at week 82.
2 context sentences(design, population, supporting numbers)
Summary · context
Both 30-week, placebo-controlled trials of 5 microg or 10 microg exenatide b.i.d. were followed by 52-week open-label, uncontrolled extension studies in which all participants received 10 microg exenatide b.i.d. and continued prior oral therapies.
Summary · context
This interim analysis includes data for 222 patients who completed 82 weeks of exenatide treatment (61% M, age 57 +/- 10 y, weight 99 +/- 21 kg, BMI 34 +/- 6 kg/m(2), HbA(1c)8.4 +/- 1.0% [mean +/- SD]).
Report a problemFND-1663411604
04HumanNon-randomized trialEfficacy outcome
In patients with type 2 diabetes, exenatide reduced HbA1c from baseline by 0.8% at week 30.
In plain wordsExenatide lowered HbA1c by 0.8% from baseline at week 30.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseHbA1c change at week 30
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Studied dose
5 microg twice daily · 30 weeksAs given in this study (human).
Measurements
HbA1c change
−0.8%
5 microg twice daily at week 30
Source sentences
Summary
Reduction in HbA(1c) from baseline to week 30 (-0.8 +/- 0.1% and -1.0 +/- 0.1% for 5 microg b.i.d. and 10 microg b.i.d., respectively [mean +/- SE]) was sustained up to week 82 (-1.0 +/- 0.1%).
2 context sentences(design, population, supporting numbers)
Summary · context
Both 30-week, placebo-controlled trials of 5 microg or 10 microg exenatide b.i.d. were followed by 52-week open-label, uncontrolled extension studies in which all participants received 10 microg exenatide b.i.d. and continued prior oral therapies.
Summary · context
This interim analysis includes data for 222 patients who completed 82 weeks of exenatide treatment (61% M, age 57 +/- 10 y, weight 99 +/- 21 kg, BMI 34 +/- 6 kg/m(2), HbA(1c)8.4 +/- 1.0% [mean +/- SD]).
Report a problemFND-1663411601
05HumanNon-randomized trialEfficacy outcome
In patients with type 2 diabetes, exenatide reduced HbA1c from baseline by 1.0% at week 30.
In plain wordsExenatide lowered HbA1c by 1.0% from baseline at week 30.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseHbA1c change at week 30
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Studied dose
10 microg twice daily · 30 weeksAs given in this study (human).
Measurements
HbA1c change
−1%
10 microg b.i.d. at week 30
Source sentences
Summary
Reduction in HbA(1c) from baseline to week 30 (-0.8 +/- 0.1% and -1.0 +/- 0.1% for 5 microg b.i.d. and 10 microg b.i.d., respectively [mean +/- SE]) was sustained up to week 82 (-1.0 +/- 0.1%).
2 context sentences(design, population, supporting numbers)
Summary · context
Both 30-week, placebo-controlled trials of 5 microg or 10 microg exenatide b.i.d. were followed by 52-week open-label, uncontrolled extension studies in which all participants received 10 microg exenatide b.i.d. and continued prior oral therapies.
Summary · context
This interim analysis includes data for 222 patients who completed 82 weeks of exenatide treatment (61% M, age 57 +/- 10 y, weight 99 +/- 21 kg, BMI 34 +/- 6 kg/m(2), HbA(1c)8.4 +/- 1.0% [mean +/- SD]).
Report a problemFND-1663411602
06HumanNon-randomized trialEfficacy outcome
In patients with type 2 diabetes, exenatide reduced weight by 1.4 kg from baseline at week 30.
In plain wordsExenatide lowered weight by 1.4 kg from baseline at week 30.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseWeight change at week 30
Study
n: not reported in source
Outcome group
Body weight · Metabolic and weight
Studied dose
5 microg twice daily · 30 weeksAs given in this study (human).
Measurements
Weight change
−1.4 kg
5 microg b.i.d. at week 30
Source sentences
Summary
Reduction of body weight from baseline to week 30 (-1.4 +/- 0.3 kg and -2.1 +/- 0.3 kg for 5 microg b.i.d. and 10 microg b.i.d., respectively) was progressive up to week 82 (-4.0 +/- 0.3 kg).
2 context sentences(design, population, supporting numbers)
Summary · context
Both 30-week, placebo-controlled trials of 5 microg or 10 microg exenatide b.i.d. were followed by 52-week open-label, uncontrolled extension studies in which all participants received 10 microg exenatide b.i.d. and continued prior oral therapies.
Summary · context
This interim analysis includes data for 222 patients who completed 82 weeks of exenatide treatment (61% M, age 57 +/- 10 y, weight 99 +/- 21 kg, BMI 34 +/- 6 kg/m(2), HbA(1c)8.4 +/- 1.0% [mean +/- SD]).
Report a problemFND-1663411605
07HumanNon-randomized trialEfficacy outcome
In patients with type 2 diabetes, exenatide reduced weight by 2.1 kg from baseline at week 30.
In plain wordsExenatide lowered weight by 2.1 kg from baseline at week 30.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseWeight change at week 30
Study
n: not reported in source
Outcome group
Body weight · Metabolic and weight
Studied dose
10 microg twice daily · 30 weeksAs given in this study (human).
Measurements
Weight change
−2.1 kg
10 microg b.i.d. at week 30
Source sentences
Summary
Reduction of body weight from baseline to week 30 (-1.4 +/- 0.3 kg and -2.1 +/- 0.3 kg for 5 microg b.i.d. and 10 microg b.i.d., respectively) was progressive up to week 82 (-4.0 +/- 0.3 kg).
2 context sentences(design, population, supporting numbers)
Summary · context
Both 30-week, placebo-controlled trials of 5 microg or 10 microg exenatide b.i.d. were followed by 52-week open-label, uncontrolled extension studies in which all participants received 10 microg exenatide b.i.d. and continued prior oral therapies.
Summary · context
This interim analysis includes data for 222 patients who completed 82 weeks of exenatide treatment (61% M, age 57 +/- 10 y, weight 99 +/- 21 kg, BMI 34 +/- 6 kg/m(2), HbA(1c)8.4 +/- 1.0% [mean +/- SD]).
Report a problemFND-1663411606
08HumanNon-randomized trialSafety outcome
In patients with type 2 diabetes, the most frequent adverse events during exenatide treatment were nausea and hypoglycaemia, both generally mild to moderate in intensity.
In plain wordsThe most frequent side effects during exenatide treatment were nausea and low blood sugar, both generally mild to moderate.
Peptide
Exenatide (exendin-4)
Outcome
Not applicableMost frequent adverse events (nausea and hypoglycaemia)
Study
n: not reported in source
Outcome group
Adverse events · Whole body
Studied dose
10 microg twice daily · 82 weeksAs given in this study (human).
Source sentences
Summary
The most frequent adverse events were nausea and hypoglycaemia, both generally mild to moderate in intensity.
2 context sentences(design, population, supporting numbers)
Summary · context
Both 30-week, placebo-controlled trials of 5 microg or 10 microg exenatide b.i.d. were followed by 52-week open-label, uncontrolled extension studies in which all participants received 10 microg exenatide b.i.d. and continued prior oral therapies.
Summary · context
This interim analysis includes data for 222 patients who completed 82 weeks of exenatide treatment (61% M, age 57 +/- 10 y, weight 99 +/- 21 kg, BMI 34 +/- 6 kg/m(2), HbA(1c)8.4 +/- 1.0% [mean +/- SD]).
Report a problemFND-1663411608

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.